Navigation Links
Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Date:12/18/2007

SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled "In Vivo Barriers to Gene Delivery" was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided. The meeting served to inform the public and the scientific community that there were actual reasons that the much heralded promise of gene therapy had thus far failed to deliver. Perhaps, if the title of the meeting had been changed to "In Vivo Solutions to Gene Delivery," the scientists of Epeius Biotechnologies might have attended.

*(LOGO 72dpi: Send2Press.com/mediaboom/logo-epeius_72dpi.jpg)

2007 was a year that the 'experts' of all things targeted published a remarkable review article in Nature (Nature Reviews, Genetics, 2007, 8:573-587) entitled "Engineering Targeted Viral Vectors for Gene Therapy." Among the flotsam and jetsam of adenoviral shipwrecks, and the ruminative discourses on "Obstacles to Systemic Targeting," was an intriguing preface stating that "the first clinical trials have already begun to take place," and a brief notation that may be of considerable scientific interest. And we quote, "A third example is represented by the first and so far only targeted vector that has been tested in the clinic: the retroviral vector Rexin-G, which expresses a cytocidal dominant-negative form of cyclin G1." The article goes as far as to mention the fact that a number of clinical studies have "demonstrated the effectiveness of the vector" in the crucible of clinical medicine.

Ironically, 2007 is also the year in which the much acclaimed and heavily subsidized National Gene Vector Laboratories (NGVL) -- whose mission and "primary goal" as an academic vector product
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
2. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
3. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
4. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
5. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
9. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
10. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, ... a vegetable-glycol solution for use in portable vaporizers, ... the active ingredients in cannabis, cannabidiol offers consumers ... vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which are ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... July 11, 2014 The consumer marketing ... across industry sectors to better identify winning tools ... to engage with and understand consumers, as new ... make critical purchasing decisions. According ... LLC, one area where organizations can observe a ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... , SOUTH SAN FRANCISCO, Calif., July 8 Rigel Pharmaceuticals, ... Company plans to host a conference call on Thursday, July ... Members of Rigel,s senior management team and the principal investigator ... 2b TASKi2 clinical trial of R788 in rheumatoid arthritis, the ...
... OAKS, Calif., July 7 Amgen (Nasdaq: ... head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in ... advanced breast cancer met its primary and secondary endpoints ... was demonstrated for both delaying the time to the ...
Cached Medicine Technology:Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:7/12/2014)... 12, 2014 Utah Valley Entrepreneurial Forum ... with awards being bestowed to companies in revenue, and ... entrepreneur community with recognition for new ideas as well ... incoming revenue. , 25 Under 5 highlights outstanding Utah ... are under 5 years old. Award recipients were recognized ...
(Date:7/12/2014)... Restore My Vision Today is a new ... couple boasting very impressive credentials on the field of ... as a way to help consumers do without the ... respective patients’ treatments . , In particular, ... of pertinent information relevant to eye care like:, ...
(Date:7/11/2014)... July 12, 2014 Recently, MagicQuinceaneraDresses.com, the ... its new collection of 2014 Quinceanera dresses . ... who want to look fashionable without paying a large ... prices, up to 57% off. , The company’s online ... to get amazing special occasion outfits. In addition to ...
(Date:7/11/2014)... 2014 As transvaginal mesh lawsuits ... & Johnson’s Ethicon Inc. unit continue to mount ... the Texas Attorney General’s Office has acknowledged that ... mesh products used to treat pelvic organ prolapse ... from kens5.com, the probe began nearly two years ...
(Date:7/11/2014)... July 11, 2014 Volunteers from ... drug abuse this week with drug education lectures, forums ... booklet distribution in cities around the world. , Drug ... National Institute on Drug Abuse, abuse of alcohol and ... in crime, lost work, decreased productivity and healthcare. ...
Breaking Medicine News(10 mins):Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3
... and whether teens smoke , MONDAY, March 15 (HealthDay ... proclaimed to women, "You,ve come a long way, baby!" ... war on cigarette advertising that targets teens, especially teenage ... Although the 1998 settlement agreement between big tobacco and ...
... ... wrestles with their own Trillion Dollar Question: How do we increase employee productivity ... Inc. the maker of Sweat365.com, unveils “The Healthy Corp” a breakthrough product that ... ...
... March 15 To better understand and ... programs, the Midwest Business Group on Health ... employers, health management programs. The non-profit coalition of more ... results indicating that 72% of doctors surveyed agree that ...
... Food and Chemical Sensitivity , announced that Philip Voluck has joined the firm and is establishing a new company that will be known as PreviMedica Lifestyle Medicine ... ... ... ...
... ... ... ... WHITE PLAINS, N.Y. , March 15 Mission Pharmacal announced today that it will partner with the March of Dimes to distribute ...
... In an economy that seems stuck on stagnate, business is booming, thank you, for LTC Financial Partners LLC (LTCFP), one of ... firm seeks to expand its army of agents by 300 this year, an increase of about 60% over last year. , ... ... , ...
Cached Medicine News:Health News:Teen Girls Say Pink Camel in Cigarette Ads Caught Their Eye 2Health News:Teen Girls Say Pink Camel in Cigarette Ads Caught Their Eye 3Health News:Konamoxt, Inc. Redefines Corporate Wellness with The Healthy Corp, a Customizable Corporate Wellness Platform 2Health News:Konamoxt, Inc. Redefines Corporate Wellness with The Healthy Corp, a Customizable Corporate Wellness Platform 3Health News:Doctors Support Efforts of Employers and Health Plans to Improve Health of Patients 2Health News:Doctors Support Efforts of Employers and Health Plans to Improve Health of Patients 3Health News:Doctors Support Efforts of Employers and Health Plans to Improve Health of Patients 4Health News:Doctors Support Efforts of Employers and Health Plans to Improve Health of Patients 5Health News:Cell Science Systems Recruits Seasoned Executive to Head New Lifestyle Medicine & Nutritional Solution for Health Care Professionals 2Health News:Cell Science Systems Recruits Seasoned Executive to Head New Lifestyle Medicine & Nutritional Solution for Health Care Professionals 3Health News:Cell Science Systems Recruits Seasoned Executive to Head New Lifestyle Medicine & Nutritional Solution for Health Care Professionals 4Health News:Mission Pharmacal and March of Dimes Share Commitment to Healthy Babies 2Health News:Mission Pharmacal and March of Dimes Share Commitment to Healthy Babies 3Health News:Mission Pharmacal and March of Dimes Share Commitment to Healthy Babies 4Health News:Long Term Care Insurance Leader Seeks 320 New Agents in 2010, Following Strong 2009 Growth 2Health News:Long Term Care Insurance Leader Seeks 320 New Agents in 2010, Following Strong 2009 Growth 3Health News:Long Term Care Insurance Leader Seeks 320 New Agents in 2010, Following Strong 2009 Growth 4
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... The Wet-Field Coagulator provides precise episcleral, ... peripheral tissue trauma. Controlled Rf diathermy ... comprehensive line of bipolar Eraser instruments, ... enhanced features that ensure a high ...
Medicine Products: